BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis

FRA:BRM • US1101221083

51.13 EUR
0 (0%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Taking everything into account, BRM scores 4 out of 10 in our fundamental rating. BRM was compared to 55 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM is valued quite cheap, but it does not seem to be growing. Finally BRM also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • BRM had positive earnings in the past year.
  • In the past year BRM had a positive cash flow from operations.
  • Of the past 5 years BRM 4 years were profitable.
  • Of the past 5 years BRM 4 years had a positive operating cash flow.
BRM.DE Yearly Net Income VS EBIT VS OCF VS FCFBRM.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B

1.2 Ratios

  • BRM has a Return On Assets (6.23%) which is comparable to the rest of the industry.
  • With a decent Return On Equity value of 32.55%, BRM is doing good in the industry, outperforming 78.18% of the companies in the same industry.
  • BRM has a better Return On Invested Capital (16.42%) than 72.73% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BRM is below the industry average of 14.21%.
  • The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROIC 16.42%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
BRM.DE Yearly ROA, ROE, ROICBRM.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • Looking at the Profit Margin, with a value of 12.57%, BRM is in line with its industry, outperforming 47.27% of the companies in the same industry.
  • BRM has a better Operating Margin (33.51%) than 80.00% of its industry peers.
  • In the last couple of years the Operating Margin of BRM has declined.
  • Looking at the Gross Margin, with a value of 73.15%, BRM is in line with its industry, outperforming 56.36% of the companies in the same industry.
  • BRM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
BRM.DE Yearly Profit, Operating, Gross MarginsBRM.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BRM is creating value.
  • There is no outstanding debt for BRM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRM.DE Yearly Shares OutstandingBRM.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
BRM.DE Yearly Total Debt VS Total AssetsBRM.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 2.33 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • BRM has a Altman-Z score of 2.33. This is comparable to the rest of the industry: BRM outperforms 43.64% of its industry peers.
  • The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
  • BRM has a better Debt to FCF ratio (3.20) than 65.45% of its industry peers.
  • BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.41, BRM is not doing good in the industry: 83.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Altman-Z 2.33
ROIC/WACC1.95
WACC8.43%
BRM.DE Yearly LT Debt VS Equity VS FCFBRM.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that BRM should not have too much problems paying its short term obligations.
  • BRM has a Current ratio of 1.27. This is in the lower half of the industry: BRM underperforms 61.82% of its industry peers.
  • A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
  • BRM has a better Quick ratio (1.17) than 67.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.17
BRM.DE Yearly Current Assets VS Current LiabilitesBRM.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 439.47% over the past year.
  • BRM shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.16% on average over the next years.
  • Based on estimates for the next years, BRM will show a decrease in Revenue. The Revenue will decrease by -5.36% on average per year.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BRM.DE Yearly Revenue VS EstimatesBRM.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
BRM.DE Yearly EPS VS EstimatesBRM.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • BRM is valuated reasonably with a Price/Earnings ratio of 9.87.
  • 89.09% of the companies in the same industry are more expensive than BRM, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (27.97), we can say BRM is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 9.98, the valuation of BRM can be described as very reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 83.64% of the companies listed in the same industry.
  • BRM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.96.
Industry RankSector Rank
PE 9.87
Fwd PE 9.98
BRM.DE Price Earnings VS Forward Price EarningsBRM.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 90.91% of the companies listed in the same industry.
  • BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 98.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.08
EV/EBITDA 7.38
BRM.DE Per share dataBRM.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • BRM's earnings are expected to decrease with -3.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • BRM has a Yearly Dividend Yield of 4.21%, which is a nice return.
  • BRM's Dividend Yield is rather good when compared to the industry average which is at 1.92. BRM pays more dividend than 87.27% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, BRM pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.21%

5.2 History

  • On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
BRM.DE Yearly Dividends per shareBRM.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • BRM pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
  • The Dividend Rate of BRM has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
BRM.DE Yearly Income VS Free CF VS DividendBRM.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B -5B 10B 15B
BRM.DE Dividend Payout.BRM.DE Dividend Payout, showing the Payout Ratio.BRM.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BRISTOL-MYERS SQUIBB CO

FRA:BRM (2/13/2026, 7:00:00 PM)

51.13

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap104.09B
Revenue(TTM)N/A
Net Income(TTM)6.04B
Analysts70.59
Price Target48.84 (-4.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.21%
Yearly Dividend2.04
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)3.55%
PT rev (3m)7.28%
EPS NQ rev (1m)-32.94%
EPS NQ rev (3m)-32.35%
EPS NY rev (1m)-8.07%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)-0.02%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.65%
Valuation
Industry RankSector Rank
PE 9.87
Fwd PE 9.98
P/S 2.57
P/FCF 8.08
P/OCF 7.44
P/B 6.66
P/tB N/A
EV/EBITDA 7.38
EPS(TTM)5.18
EY10.13%
EPS(NY)5.12
Fwd EY10.02%
FCF(TTM)6.33
FCFY12.38%
OCF(TTM)6.88
OCFY13.45%
SpS19.87
BVpS7.67
TBVpS-9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.91
Profitability
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROCE 23.41%
ROIC 16.42%
ROICexc 21.58%
ROICexgc 109.99%
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
FCFM 31.86%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Debt/EBITDA 2.13
Cap/Depr 26.84%
Cap/Sales 2.75%
Interest Coverage 7.66
Cash Conversion 79.11%
Profit Quality 253.39%
Current Ratio 1.27
Quick Ratio 1.17
Altman-Z 2.33
F-Score6
WACC8.43%
ROIC/WACC1.95
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year220.11%
EBIT Next 3Y49.61%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%

BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ

What is the fundamental rating for BRM stock?

ChartMill assigns a fundamental rating of 4 / 10 to BRM.DE.


What is the valuation status of BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.


How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 4 / 10.


What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?

The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -1.05% in the next year.


Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?

The dividend rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 7 / 10 and the dividend payout ratio is 82.81%.